Although there was no resulting benefit to overall survival with the addition of short-term androgen deprivation to dose-escalated radiotherapy, patients with intermediate-risk prostate cancer experienced other disease benefits with this treatment approach.
Patients receiving trastuzumab for HER2-positive breast cancer on the phase 3 HERA trial did not have an increased risk of cardiotoxicity from radiation therapy.
Patients who were treated with extreme hypofractionation after breast conserving surgery saw no increase in ill-treatment effects compared with those receiving moderate hypofractionation.
A retrospective review found that external-beam radiation therapy has been underutilized as a bridging therapy in patients with hepatocellular carcinoma seeking transplant, although its prevalence has increased over the past decade.
Investigators believe that a systems-based intervention could reduce or even eliminate racial gaps in cancer treatment completion and improve outcomes.
Stereotactic body radiotherapy added to standard of care treatment resulted in better progression-free survival for those with oligoprogressive non–small cell lung cancer.
This study found that found that mini-strokes and heart attacks were significantly less common among patients with locally advanced non-small cell lung cancer who underwent proton therapy versus conventional photon-based radiation therapy.
In working patients with head and neck cancer receiving radiotherapy, weight loss and an increase in pain, fatigue, and ECOG status were all found to be significantly associated with reductions in working days per week.
This study suggested that the racial composition of clinical trials involving radiation therapy does not match that of the overall US population.
A study presented at the ASTRO Annual Meeting found that adding the advanced PET radiotracer fluciclovine (Axumin) to conventional imaging for patients with recurrent prostate cancer may improve disease-free survival rates.
“Sexual dysfunction is an unfortunately common side effect of cancer treatment, and there appears to be a large gender disparity in how physicians discuss sexual health with their patients,” said lead study author James Taylor, MD, MPH.
Researchers found there has been a 17% growth in radiation therapy facilities over the last 15 years, with expansion specifically improving for those who already live near such facilities.
This study indicated that patients with up to 3 lung metastases from primary tumors in other sites who were treated with stereotactic body radiation therapy fared comparably well whether their radiation was delivered in 1 or 4 treatment sessions.
Stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving the complete response rate for pain related to spinal metastases at 3- and 6-months post-radiation.
When compared with whole brain radiation therapy, researchers discovered highly focused radiation therapy led to less cognitive decline while simultaneously delivering equivalent overall survival rates.
This peer-to-peer exchange highlights results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.
In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.
This video highlights an education session on the challenge of perineural invasion in head and neck cancer from the 2017 ASTRO Annual Meeting.
This video highlights a large-scale profiling effort that seeks to identify and classify mutant alleles driving resistance to radiation therapy across different cancer types.
This video examines patient fears and misconceptions regarding radiation therapy for the treatment of breast cancer.
This video examines results of a study that looked at treatment tolerability in elderly patients with HPV-positive oropharyngeal squamous cell carcinoma.
This video examines changes in insurance status after implementation of the Affordable Care Act among cancer patients who received radiation therapy.
This video highlights a recent study that looked at the survival impact of cancer patients who chose alternative medicine instead of conventional cancer treatments.
This video reviews outcomes among breast cancer patients in the United States who refused recommended therapy for their cancer.
This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.
This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.
This video reviews 4-year quality-of-life results from a prospective, population-based study that looked at prostate cancer patients who selected either active surveillance, radical prostatectomy, or external-beam radiation.
This video highlights a new study that found that markers of immune response in prostate cancer may be able to predict patients’ response to radiation therapy, likelihood of recurrence, and survival.
This video highlights studies on advanced lung cancer with practice-changing potential presented at the 2017 ASTRO Annual Meeting.
This video highlights potentially practice-changing studies on genitourinary cancers presented at the 2017 ASTRO Annual Meeting.
